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Objective:  22 
The objective of our study was to estimate the procedure-related risks of miscarriage following 23 
CVS and amniocentesis in a large unselected screened and to determine whether these risks 24 
are consistent with those reported in systematic reviews and meta-analysis.  25 
Methods:  26 
This was a retrospective cohort study undertaken at a large Fetal Medicine Unit in the United 27 
Kingdom during the period of January 2009 to May 2018. We included all singleton pregnancies 28 
that booked at our unit before 20 weeks after excluding those with multiple pregnancies, major 29 
fetal defects, terminations and lost to follow-up. We estimated the risk of miscarriage in those 30 
that had a CVS or amniocentesis as well as those that did not have any invasive procedure, to 31 
estimate the procedure-related risk as a risk-difference (95% confidence interval [CI]). Univariate 32 
and multivariate regression analysis was used to derive odds ratios (OR) (95%CI) and determine 33 
which maternal and pregnancy characteristics provided a significant contribution in prediction of 34 
miscarriage and whether CVS or amniocentesis provided a significant independent. 35 
Results: 36 
During the study period, there were 45,120 singleton pregnancies, including 1,546 that had an 37 
invasive procedure. We  excluded 1,429 pregnancies (3.2%), due to fetal defects, termination of 38 
pregnancy or those with missing outcomes. In pregnancies that underwent CVS, the risk of 39 
miscarriage was 1.5% (13/861), compared to 1.2% (476/39,152) in pregnancies that did not 40 
have a procedure (p=0.437). In pregnancies that underwent an amniocentesis, the risk of 41 
miscarriage was 0.8% (3/375), compared to 1.2% (491/42,463) in those that did not (p=0.520). 42 
Univariate and multivariate regression analysis demonstrated that there was no significant 43 
prediction to the risk of miscarriage from CVS (p=0.399; p=0.592, respectively) or amniocentesis 44 
(p=0.543; p=0.550, respectively). The risk of procedure-related loss attributed to CVS was 45 
0.29% (95%CI: -0.53-1.12) and that following amniocentesis was -0.36% (95%CI: -1.26-0.55), 46 
which was not significantly different from those that did not have any procedure. 47 
Conclusion:  48 
The procedure-related risks of miscarriage following CVS and amniocentesis are considerably 49 
lower than currently quoted. The estimates of risks based on our study are 0.29% for CVS and -50 





Amniocentesis and chorionic villus sampling (CVS) are invasive procedures carried out for 54 
prenatal diagnosis. It is essential that women are provided with accurate evidence-based 55 
information regarding risks of miscarriage from these invasive procedures. However, there is still 56 
considerable variation in recommendations from professional bodies regarding procedure-57 
related risks of miscarriage quoted to women, with some reporting that the additional risk 58 
following a CVS is up to 1-2% and that following an amniocentesis is 1%1-5. There are recent 59 
systematic reviews and meta-analysis, as well as large population and cohort studies, which 60 
report that the procedure-related risks of miscarriage following invasive procedures carried out 61 
by specialists in Fetal Medicine Centres are much lower than currently reported6-11. There is a 62 
need to update and standardise information provided to women to allow them to make informed 63 
decisions based on accurate figures.   64 
 65 
The objective of our study was to estimate the procedure-related risks of miscarriage following 66 
CVS and amniocentesis in a large unselected screened population in large specialist Fetal 67 
Medicine Unit and to determine whether these risks are consistent with those reported in 68 
systematic reviews and meta-analysis.  69 
 70 
 71 
Materials and Methods 72 
 73 
Study population 74 
This was a retrospective cohort study undertaken at the Fetal Medicine Centre at Medway NHS 75 
Foundation Trust, in the United Kingdom during the period of 1st January 2009 to 31st May 2018. 76 
In our unit, all women booking for their pregnancy care prior to 14 weeks’ gestation are offered 77 
an appointment at 11-13 weeks’ for dating of the pregnancy by measurement of fetal crown-78 
rump length (CRL), assessment of fetal anatomy and combined screening for trisomies 13,18 79 
and 21. The assessment of risk for aneuploidies from combined screening is based on maternal 80 
age, measurement of fetal nuchal translucency (NT) thickness and maternal serum free β-81 
human chorionic gonadotrophin (β-hCG) and pregnancy associated plasma protein-A (PAPP-A) 82 
12-14. Women booking after 14 weeks’ are offered scan to date the pregnancy, assess fetal 83 
anatomy and assessment of risk of fetal aneuploidies from second trimester serum biochemical 84 
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testing15. At each of these visits, we record maternal demographic characteristics and medical 85 
history on an electronic database (Viewpoint version 5.6; General Electric Company). 86 
 87 
Invasive procedures 88 
Women who were deemed to be at high-risk for fetal aneuploidies or those with major defects 89 
were offered the option of an invasive prenatal diagnosis. CVS is offered as the procedure of 90 
choice up to 15 weeks’ gestation and amniocentesis is offered after this gestational age. All 91 
procedures were either carried out either by a specialist in Fetal Medicine or by trainees under 92 
direct supervision of the specialist. All procedures were carried out transabdominally under direct 93 
ultrasound guidance with a free-hand technique and using standard antiseptic precautions for 94 
outpatient procedures with no routine use of antibiotic prophylaxis before or after the procedure. 95 
The CVS procedures were carried out with 17G x 17cm linear echo CVS needle (Rocket® LXTM 96 
Chorionic Villus Sampling Set, Rocket Medical PLC, Tyne and Wear, NE38 9BZ, United 97 
Kingdom). The amniocentesis procedures were carried out with 22G x 15 cm EchoTip® 98 
amniocentesis needle, Cook Medical, Bloomington, USA).   99 
 100 
Inclusion criteria 101 
The inclusion criteria were all singleton pregnancies which booked at our hospital and Fetal 102 
Medicine Centre for their pregnancy care before 20 week’s gestation. We excluded multiple 103 
pregnancies, pregnancies with major fetal defects, termination of pregnancies and those lost to 104 
follow-up. All pregnancies meeting the inclusion criteria were divided into two groups: invasive 105 
group, which had either a CVS or an amniocentesis and a group that did not have any invasive 106 
procedures. Miscarriage was defined as a pregnancy loss prior to 24 weeks’ gestation. We 107 
compared the risks of miscarriage in pregnancies undergoing CVS and amniocentesis and 108 
compared them to those that did not have any invasive procedure. The procedure-related risk of 109 
pregnancy loss following any invasive procedure was calculated as a risk-difference between 110 
the two groups. 111 
 112 
Statistical analysis 113 
Comparison of the maternal and pregnancy characteristics in the outcome groups was by the χ2-114 
square test and Fisher’s exact test for categorical variables and Mann-Whitney U-test for 115 
continuous variables, respectively. Significance was assumed at 5% and post hoc Bonferroni 116 




Data for risks of miscarriage were entered into contingency tables and absolute risks were 119 
estimated by determining the prevalence of miscarriage in the study groups. Univariate and 120 
multivariate logistic regression analysis was used to determine which of the maternal and 121 
pregnancy characteristics provided a significant contribution in prediction of miscarriage. To 122 
determine whether either CVS or an amniocentesis had any significant independent prediction of 123 
miscarriage, we estimated unadjusted and adjusted odds from univariate and multivariate 124 
regression analysis to derive odds ratio (OR) (95% confidence intervals [CI]). The estimates of 125 
procedure-related risks of miscarriage from CVS or amniocentesis were calculated as a risk-126 
difference (95%CI).  127 
 128 
The statistical package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, Armonk, 129 





Study population 135 
During the study period of 1st January 2009 to 31st May 2018, 45,120 singleton pregnancies 136 
were booked for their pregnancy care at our hospital. In this population, there were 43,574 137 
(96.6%) who did not any invasive procedures and 1,546 (3.4%) who had an invasive procedure 138 
prenatal diagnosis, including 1142 (73.9%) who had CVS and 419 (27.1%) who had an 139 
amniocentesis. We excluded 1,429 pregnancies (3.2%), due to major fetal defects or those that 140 
ended in termination of pregnancies (n=475) and those with missing follow-up data for the 141 
pregnancy (n=954). The study population therefore included 43,691 singleton pregnancies with 142 
complete outcome data, including 507 (1.2%) that ended in miscarriage prior to 24 weeks’ 143 
gestation and 43,184 (98.8%) that delivered a phenotypically normal neonate. Out of the study 144 
population of 43,691 pregnancies, there were 40,013 (91.6%) that had first-trimester combined 145 
screening and 3,678 (8.4%) pregnancies that booked late between 14 and 24 weeks’ gestation. 146 
In these study groups, we carried out 1,228 invasive procedures, including 861 (70.1%) that had 147 
CVS and 375 (30.5%) that had an amniocentesis, including 8 (0.7%) that had both a CVS and 148 
amniocentesis. 149 
 150 
The maternal and pregnancy characteristics in the study groups are compared in Table 1. In 151 
pregnancies that ended in miscarriage compared to those that did not, the median maternal 152 
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height was smaller, there were more women with Afro-Caribbean, South Asian, East Asian and 153 
Mixed racial origin, more women who conceived following assisted conception and and higher 154 
prevelance of pregnancies with chronic hypertension. The maternal characteristics in 155 
pregnancies that underwent a CVS or an amniocentesis, compared to those that did not are 156 
compared in Supplementary Tables 1 and 2. 157 
 158 
Factors predicting risk of miscarriage in study population 159 
The maternal and pregnancy characteristics associated with risk of miscarriage were examined 160 
with univariate and multivariate regression analysis (Table 2). After adjustment for confounding 161 
factors in multivariate analysis, the maternal characteristics associated with a subsequent risk of 162 
miscarriage following a first trimester scan at 11-14 week’s gestation were advanced maternal 163 
age, weight and height, racial origin, method of conception and parity and chronic hypertension 164 
but not cigarette smoking or other medical disorders such as diabetes mellitus, epilepsy, asthma 165 
or thyroid disorders. These maternal characteristics providing a significant contribution in the 166 
multivariate analysis formed the a-priori risk for miscarriage. The components of first trimester 167 
combined screening which provided a significant contribution in prediction of miscarriage were 168 
log10 a-priori risk, an increased fetal NT≥95th percentile, serum PAPP-A MoM≤0.3 and a 169 
reversed a-wave in the ductus venosus but not serum free β-HCG MoM (p=0.913).  170 
 171 
Procedure-related risk of miscarriage after CVS and amniocentesis 172 
In the study population, the risk of miscarriage following invasive prenatal diagnostic procedures 173 
was 1.3% (16/1228) compared to 1.2% (491/42,463) in pregnancies that did not have any 174 
invasive procedure (p=0.636). Univariate regression analysis demonstrated that there was no 175 
significant prediction to the risk of miscarriage from invasive procedures (p=0.636). Multivariate 176 
regression analysis demonstrated that the addition of invasive procedures to the combination of 177 
log10 a-priori risk from maternal factors and components of first trimester combined screening 178 
including fetal NT, serum PAPP-A MoM and flow in ductus venosus, did not provide any 179 
significant contribution (p=0.415) to the prediction of miscarriage. The risk of procedure-related 180 
loss attributed to any invasive procedure was 0.1% (95%CI: -0.5 to 0.8), which was not 181 
significantly different from those that did not have any procedure. 182 
 183 
In pregnancies that underwent CVS, the risk of miscarriage was 1.5% (13/861), compared to 184 
1.2% (476/39,152) in pregnancies that had first trimester combined screening and no invasive 185 
procedure (p=0.437). Univariate regression analysis demonstrated that there was no significant 186 
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prediction to the risk of miscarriage from CVS (p=0.399). Multivariate regression analysis 187 
demonstrated that the addition of CVS to the combination of log10 a-priori risk from maternal 188 
factors and components of first trimester combined screening including fetal NT, serum PAPP-A 189 
MoM and flow in ductus venosus, did not provide any significant contribution (p=0.592) to the 190 
prediction of miscarriage. The risk of procedure-related loss attributed to CVS was 0.29% 191 
(95%CI: -0.53 to 1.12; p=0.483), which was not significantly different from those that did not 192 
have any procedure. 193 
 194 
In pregnancies that underwent an amniocentesis, the risk of miscarriage was 0.8% (3/375), 195 
compared to 1.2% (491/42,463) in pregnancies that did not have any invasive procedure during 196 
the pregnancy (p=0.520). Univariate regression analysis demonstrated that there was no 197 
significant prediction to the risk of miscarriage from amniocentesis (p=0.543). Multivariate 198 
regression analysis demonstrated that the addition of amniocentesis to the combination of log10 199 
a-priori risk from maternal factors, did not provide any significant contribution (p=0.550) to the 200 
prediction of miscarriage. The risk of procedure-related loss attributed to amniocentesis was -201 
0.36% (95%CI: -1.26 to 0.55; p=0.442), which was not significantly different from those that did 202 





Principal findings of the study 208 
The findings our study demonstrate that first, there is no significant increase in risks of 209 
miscarriage following a CVS or amniocentesis compared to pregnancies that had no invasive 210 
procedure; second, our findings confirm the association of miscarriage with maternal and 211 
pregnancy characteristics and third, the estimate of procedure-related risk of miscarriage from 212 
CVS is 0.29% (95%CI -0.53 to 1.12) and from amniocentesis is -0.36% (95%CI: -1.26 to 0.55).  213 
 214 
Strengths and limitations 215 
The strengths of the study are first, examination of a large unselected cohort of consecutively 216 
screened pregnancies in a large specialist Fetal Medicine Unit; second, procedures were either 217 
carried out or directly supervised by specialist Fetal Medicine Consultants; and third, accurate 218 
ascertainment of maternal and pregnancy characteristics along with pregnancy outcomes to 219 




The limitations of our study relate to the retrospective study design but we accounted for the 222 
potential biases due to this by ensuring that the study population was an unselected screened 223 
cohort over a fixed period of time, thus avoiding any selection bias in choosing any cases or 224 
controls. Similarly, the possibility of recall bias was unlikely in our study as the risk factors 225 
associated with the adverse outcome were recorded systematically in our database before the 226 
occurrence of the invasive procedure and pregnancy outcome. Thirdly, all our procedures were 227 
carried out transabdominally and therefore the estimates of risks only relate to procedures 228 
carried out transabdominally. 229 
 230 
Comparison with other studies 231 
The findings of our study are consistent with results of systematic reviews and meta-analysis 232 
which report that the procedure-related risk of miscarriage from invasive procedures is much 233 
lower than currently quoted6-11. A large nationwide population-based study of 147,987 women 234 
with a singleton pregnancy including 5,072 who underwent CVS and 1,809 who underwent 235 
amniocentesis, reported that the procedure-related risk of miscarriage at 21 days following CVS 236 
was -0.21% and that at 28 days following amniocentesis was 0.56%7.  A recent meta-analysis of 237 
large controlled studies, which took into account the results of the large Danish population-238 
based study, reported that there were 623 losses in 64,901 women who underwent 239 
amniocentesis and 327 losses in 19,000 women who underwent CVS and the procedure-related 240 
risks of miscarriage, after taking into account the miscarriage rate in controls that did not have 241 
an invasive procedure, was about 0.35% and 0.30%, respectively.8 The findings of our study are 242 
also consistent with a previous study reporting that the characteristics that are significantly 243 
associated with risks of miscarriage, such as increased fetal NT, decreased serum PAPP-A and 244 
reversed a-wave in ductus venosus, are the very factors that are associated with increased risk 245 
for aneuploidies and therefore an update of a CVS9. Therefore, in estimation of procedure-246 
related risk of invasive procedures, it is necessary to adjust for these confounding factors. The 247 
findings our study based, on a large unselected cohort of more than 45,000 pregnancies, are 248 
consistent with the results from the systematic reviews and meta-analysis, confirming that the 249 
procedure-related risks of miscarriage from invasive procedures are considerably lower than 250 
what are currently recommended by professional bodies6,8. 251 
 252 
Implications for clinical practice 253 
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The main clinical implication from our study is that the procedure-related risks of miscarriage are 254 
considerably lower than those currently informed to women and in view of these results as well 255 
as those from meta-analysis6,8, the procedure-related risks associated with CVS and 256 
amniocentesis should be revised and made uniform across all recommendations and guidelines. 257 
It is important to note that the results from our study are those from a specialist Fetal Medicine 258 
Centre, where all the procedures in the study were either undertaken or directly supervised by 259 
Fetal Medicine specialists. The results of the meta-analysis also emphasise this point as the 260 
studies that were included in the analysis were those that were done by experts in large 261 
specialist centres and therefore, the reported procedure-related risks are those from expert 262 
operators6. There is also evidence from other studies highlighting the fact that the risk of 263 
miscarriage from invasive procedures is related to the skill and experience of the operator. 264 
Therefore, it may be worthwhile to consider that invasive prenatal diagnostic procedures should 265 
be undertaken by skilled operators in specialist centres to ensure low procedure-related 266 
complications, as reported in studies, rather than the procedures being carried out by operators 267 




The procedure-related risks of miscarriage following CVS and amniocentesis in our study are 272 
considerably lower than currently quoted and consistent with the estimates of such risks 273 
reported from systematic reviews and meta-analysis. 274 
 275 
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Table 1. Maternal and pregnancy characteristics in pregnancies that miscarried compared to 328 
those that did not. 329 
IQR = interquartile range; Significance level p ** p<0.0001; *p<0.01. 330 
331 
Maternal and pregnancy characteristics  No miscarriage Miscarriage 
Sample size (n=43,184) (n=507) 
Maternal age in years, median (IQR) 28.1 (24.3-32.0) 28.0 (24.1-33.0) 
Maternal weight in kg, median (IQR) 68.8 (59.7-81.1) 69.6 (59.1-85.0) 
Maternal height in mt, median (IQR) 1.64 (1.60-1.69) 1.63 (1.59-1.67)** 
Racial origin   
   Caucasian (Reference), n (%) 39,615 (91.7) 427 (84.2) 
   Afro-Caribbean, n (%) 1,342 (3.1) 26 (5.1)* 
   South Asian, n (%) 1,860 (4.3) 40 (7.9)** 
   East Asian, n (%) 147 (0.3) 6 (1.2)** 
   Mixed, n (%) 220 (0.5) 8 (1.6)* 
Conception   
   Spontaneous (Reference), n (%) 42,497 (98.4) 489 (96.4) 
   Assisted conception, n (%) 687 (1.6) 18 (3.6)** 
Cigarette smoking, n (%) 6,558 (15.2) 86 (17.0) 
History of medical disorders   
    Chronic hypertension, n (%) 375 (0.9) 14 (2.8)** 
    Diabetes mellitus, n (%) 316 (0.7) 6 (1.2) 
    Connective tissue disorders, n (%) 63 (0.1) 0 
    Thrombophilia, n (%) 43 (0.1) 0 
    Asthma, n (%) 2,223 (5.1) 33 (6.5) 
    Epilepsy, n (%) 254 (0.6) 3 (0.6) 
Nulliparous 20,104 (46.6) 209 (41.2)* 
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Table 2. Univariate and multivariate regression analysis in prediction of miscarriage and 332 
contribution of chorionic villus sampling and amniocentesis 333 
 334 
 335 
Significance level ** p<0.0001; *p<0.01  336 
Variable  
Univariate 






Maternal age ≥40 years 2.48 (1.65-3.74)** <0.001 1.92 (1.26-2.93)* 0.001 
Maternal weight in kg 1.00 (1.00-1.01) 0.225 1.01 (1.00-1.01)* 0.005 
Maternal height in cm 0.96 (0.95-0.98)** <0.001 0.96 (0.95-0.98)** <0.001 
Racial origin     
   Caucasian (Reference) 1.00  1.00  
   Afro-Caribbean 2.00 (1.35-2.97)* 0.001 1.74 (1.16-2.60)* 0.006 
   South Asian 2.07 (1.49-2.89)** <0.001 1.80 (1.28-5.54)* 0.001 
   East Asian 4.11 (1.80-9.37)* 0.001 3.31 (1.43-7.65)* 0.006 
   Mixed 3.83 (1.88-7.82)** <0.001 3.77 (1.84-7.73)** <0.001 
Method of conception     
  Spontaneous (Reference) 1.00  1.00  
  Assisted conception 2.06 (1.27-3.37) 0.004 1.92 (1.16-3.19)* 0.023 
Cigarette smoking 1.20 (0.95-1.52) 0.128 - - 
History of medical disorders     
    Chronic hypertension 3.34 (1.95-5.74)** <0.001 2.70 (1.55-4.71)** <0.001 
    Diabetes mellitus 1.40 (0.57-3.39) 0.462 - - 
    Asthma 1.31 (0.92-1.87) 0.137 - - 
    Epilepsy 1.03 (0.33-3.23) 0.960 - - 
Maternal / pregnancy characteristics 
Maternal characteristics (Log10 a-priori) 10.61 (6.94-16.23)** <0.001 10.56 (6.66-16.64)** <0.001 
Fetal NT ≥95th percentile 3.34 (2.18-5.11)** <0.001 2.91 (1.75-4.86)** <0.001 
Reversed a-wave in ductus venosus 2.58 (1.53-4.35)** <0.001 2.22 (1.24-4.00)* 0.008 
Serum free β-HCG MoM ≤0.3 MoM 1.59 (0.82-3.10) 0.171 - - 
Serum PAPP-A MoM ≤0.3 MoM 2.63 (1.70-4.06)** <0.001 2.46 (1.59-3.81)** <0.001 
Invasive procedure 
Chorionic villus sampling 1.27 (0.73-2.21) 0.399 - - 
Amniocentesis 0.69 (0.22-2.16) 0.543 - - 
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Supplementary Table 1. Maternal and pregnancy characteristics in pregnancies undergoing 337 
chorionic villus sampling compared to those that did not have an invasive procedure. 338 
IQR = interquartile range; PAPP-A = pregnancy associated plasma protein-A; MoM = Multiple of 339 
expected median; Significance level p ** p<0.0001; *p<0.01. 340 





Sample size (n=37,152) (n=861) 
Maternal age in years, median (IQR) 28.1 (24.3-32.0) 33.2 (28.1-37.4)** 
Maternal weight in kg, median (IQR) 69.0 (59.9-81.5) 69.0 (59.9-81.5) 
Maternal height in mt, median (IQR) 1.64 (1.60-1.69) 1.64 (1.60-1.69) 
Racial origin   
   Caucasian, n (%) 36,082 (92.2) 755 (87.7) 
   Afro-Caribbean, n (%) 1,137 (2.9) 46 (5.3)** 
   South Asian, n (%) 1,635 (4.2) 41 (4.8) 
   East Asian, n (%) 118 (0.3) 12 (1.4)** 
   Mixed, n (%) 180 (0.5) 7 (0.8) 
Method of conception   
   Spontaneous (Reference), n (%) 38,468 (98.3) 848 (98.5) 
   Assisted conception, n (%) 684 (1.7) 13 (1.5) 
Cigarette smoking, n (%) 5,802 (14.8) 110 (12.8) 
History of medical disorders   
    Chronic hypertension, n (%) 345 (0.9) 18 (2.1)** 
    Diabetes mellitus, n (%) 285 (0.7) 13 (1.5)* 
    Connective tissue disorders, n (%) 59 (0.2) 0 
    Thrombophilia, n (%) 42 (0.1) 1 (0.1) 
    Asthma, n (%) 2,101 (5.4) 28 (3.3)* 
    Epilepsy, n (%) 234 (0.6) 4 (0.5) 
Nulliparous 17,840 (45.6) 310 (36.0)** 
First trimester combined screening   
    Fetal crown-rump length in mm, median (IQR) 64.8 (59.3-71.0) 68.3 (61.3-74.3)* 
    Fetal nuchal translucency ≥ 95th percentile, n (%) 365 (0.9) 201 (25.3)** 
    Reversed a-wave in ductus venosus, n (%) 417 (1.1) 55 (6.9)** 
    Serum free β-HCG MoM, median (IQR) 1.03 (0.70-1.53) 1.42 (0.84-2.34) 
    Serum PAPP-A MoM, median (IQR) 0.99 (0.69-1.41) 0.57 (0.35-0.96) 
Pregnancy outcome   
    Gestation age at delivery in weeks, median (IQR) 39.6 (38.6-40.5) 39.2 (38.1-40.3)* 
    Birthweight in grams, median (IQR) 3420 (3075-3760) 3345 (2970-3710)* 
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Sample size (n=42,463) (n=375) 
Maternal age in years, median (IQR) 28.1 (24.2-32.0) 29.0 (23.6-35.0) 
Maternal weight in kg, median (IQR) 68.8 (59.7-81.2) 67.0 (60.4-79.0) 
Maternal height in mt, median (IQR) 1.64 (1.60-1.69) 1.64 (1.59-1.67) 
Racial origin   
   Caucasian (Reference), n (%) 38,958 (91.7) 337 (89.9) 
   Afro-Caribbean, n (%) 1,307 (3.1) 15 (4.0) 
   South Asian, n (%) 1,838 (4.3) 21 (5.6) 
   East Asian, n (%) 140 (0.3) 1 (0.3) 
   Mixed, n (%) 220 (0.5) 1 (0.3) 
Conception   
   Spontaneous (Reference), n (%) 41,773 (98.4) 372 (99.2) 
   Assisted conception, n (%) 690 (1.6) 3 (0.8) 
Cigarette smoking, n (%) 6,469 (15.2) 66 (17.6) 
History of medical disorders   
    Chronic hypertension, n (%) 369 (0.9) 2 (0.5) 
    Diabetes mellitus, n (%) 303 (0.7) 6 (1.6) 
    Connective tissue disorders, n (%) 61 (0.1) 2 (0.5) 
    Thrombophilia, n (%) 42 (0.1) 0 
    Asthma, n (%) 2,208 (5.2) 20 (5.3) 
    Epilepsy, n (%) 250 (0.6) 3 (0.8) 
Nulliparous 19,844 (46.7) 162 (43.2) 
Pregnancy outcome   
    Gestation age at delivery in weeks, median (IQR) 39.6 (38.5-40.5) 39.1 (37.5-40.3) 
    Birthweight in grams, median (IQR) 3415 (3070-3750) 3170 (2682-3630) 
